C12N 2770/16071
Demonstrated in vivo effect
C12N2770/16071 (Demonstrated in vivo effect) appears on 9 US grants and 18 published applications in this corpus.
Search patents in C12N- Granted patents
- 9
- Published applications
- 18
- Assignees
- 12
- Inventors
- 32
- Latest grant
- 20 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2016 | 0 | 2 |
| 2017 | 0 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 1 |
| 2020 | 0 | 2 |
| 2021 | 1 | 1 |
| 2022 | 0 | 1 |
| 2023 | 2 | 4 |
| 2024 | 2 | 0 |
| 2025 | 2 | 4 |
| 2026 | 2 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Artificial RNA molecules encoding a norovirus antigen and uses thereof20 Jan 2026US 12,527,856 B2CureVac AG
- Nucleic acid molecules and uses thereof6 Jan 2026US 12,514,918 B2CureVac AG
- Rabbit haemorrhagic disease virus (RHDV) vaccines23 Dec 2025US 12,503,493 B2
- Sapovirus vaccines29 Jul 2025US 12,371,455 B2Vst LLC
- Compositions comprising a norovirus nucleic acid and methods of use thereof17 Dec 2024US 12,168,050 B2CureVac AG
- Norovirus mrna vaccines10 Sep 2026US 2026/0263582 A1ModernaTX, Inc.
- Nucleic acid molecules and uses thereof21 May 2026US 2026/0137769 A1CureVac AG
- Nucleic acid molecules and uses thereof28 Aug 2025US 2025/0269007 A1CureVac AG
- Nucleic acid molecules and uses thereof27 Feb 2025US 2025/0064915 A1CureVac AG
- Hexavalent norovirus vlp vaccine and a preparation method thereof23 Jan 2025US 2025/0025546 A1Chengdu Kanghua Biological Products Co., Ltd.
Most cited
By later US patents
- Artificial nucleic acid molecules encoding a norovirus antigen and uses thereof30US 11,141,474 B2CureVac AG · 2021
- Compositions comprising a norovirus nucleic acid and methods of use thereof2US 12,168,050 B2CureVac AG · 2024
- Norovirus fusion proteins and VLPS comprising norovirus fusion proteins1US 11,608,361 B2Medicago Inc. · 2023